Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(10):1655–1659. doi: 10.1038/bjc.1996.605

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.

S D Fosså 1, C Sternberg 1, H I Scher 1, C H Theodore 1, B Mead 1, D Dearnaley 1, J T Roberts 1, E Skovlund 1
PMCID: PMC2074866  PMID: 8932351

Abstract

The aim of the present retrospective study was to assess long-term survival after cisplatin-based chemotherapy in 398 patients with advanced urothelial transitional cell carcinoma (TCC) treated at seven international oncological units. Various combinations of cisplatin, methotrexate, vinblastine (or vincristine) and doxorubicin were used. The complete response rate according to the WHO criteria was 17%. Partial responses were obtained in 42% of the patients. The overall cancer-related 2 year and 5 year survival rates were 21% and 11% respectively. Based on multivariate analyses, a good prognosis group could be identified comprising patients with a good performance status with disease confined to lymph nodes (14%) or patients with T4b disease only. These patients had a 28% 5 year survival rate, which, in part, has to be related to post-chemotherapy consolidation treatment in patients with pelvis-confined disease (radiotherapy, 26%; total cystectomy, 11%). Fifteen patients died of chemotherapy-related complications and in 16% of the patients toxicity led to discontinuation of treatment. Modern cisplatin-based chemotherapy leads to long-term survival and cure of selected patients with advanced urothelial transitional cancer. In routine clinical practice, chemotherapy should be offered to good prognosis patients; those presenting with a good performance status and a non-metastasising T4b tumour or with metastases confined to lymph nodes. Post-chemotherapy consolidation treatment by surgery or radiotherapy should always be considered. Such chemotherapy requires oncological expertise in order to avoid unnecessary toxicity.

Full text

PDF
1655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boccardo F., Pace M., Guarneri D., Canobbio L., Curotto A., Martorana G. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Cancer. 1994 Apr 1;73(7):1932–1936. doi: 10.1002/1097-0142(19940401)73:7<1932::aid-cncr2820730726>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  2. Dimopoulos M. A., Finn L., Logothetis C. J. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol. 1994 Mar;151(3):598–601. doi: 10.1016/s0022-5347(17)35025-5. [DOI] [PubMed] [Google Scholar]
  3. Fosså S. D., Harland S. J., Kaye S. B., Raghavan D., Russell J. M., Parmar M. K., Uscinska B. M., Wood R. Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party). Br J Urol. 1992 Aug;70(2):161–168. doi: 10.1111/j.1464-410x.1992.tb15696.x. [DOI] [PubMed] [Google Scholar]
  4. Gabrilove J. L., Jakubowski A., Scher H., Sternberg C., Wong G., Grous J., Yagoda A., Fain K., Moore M. A., Clarkson B. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988 Jun 2;318(22):1414–1422. doi: 10.1056/NEJM198806023182202. [DOI] [PubMed] [Google Scholar]
  5. Geller N. L., Sternberg C. N., Penenberg D., Scher H., Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 1991 Mar 15;67(6):1525–1531. doi: 10.1002/1097-0142(19910315)67:6<1525::aid-cncr2820670611>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  6. Harker W. G., Meyers F. J., Freiha F. S., Palmer J. M., Shortliffe L. D., Hannigan J. F., McWhirter K. M., Torti F. M. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol. 1985 Nov;3(11):1463–1470. doi: 10.1200/JCO.1985.3.11.1463. [DOI] [PubMed] [Google Scholar]
  7. Jeffery G. M., Mead G. M. CMV chemotherapy for advanced transitional cell carcinoma. Br J Cancer. 1992 Sep;66(3):542–546. doi: 10.1038/bjc.1992.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Loehrer P. J., Sr, Einhorn L. H., Elson P. J., Crawford E. D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M. F., Lowe B. A. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992 Jul;10(7):1066–1073. doi: 10.1200/JCO.1992.10.7.1066. [DOI] [PubMed] [Google Scholar]
  9. Logothetis C. J., Dexeus F. H., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990 Jun;8(6):1050–1055. doi: 10.1200/JCO.1990.8.6.1050. [DOI] [PubMed] [Google Scholar]
  10. Logothetis C. J., Samuels M. L., Ogden S., Dexeus F. H., Swanson D., Johnson D. E., von Eschenbach A. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol. 1985 Sep;134(3):460–464. doi: 10.1016/s0022-5347(17)47240-5. [DOI] [PubMed] [Google Scholar]
  11. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  12. Miller R. S., Freiha F. S., Reese J. H., Ozen H., Torti F. M. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol. 1993 Jul;150(1):65–69. doi: 10.1016/s0022-5347(17)35398-3. [DOI] [PubMed] [Google Scholar]
  13. Sengeløv L., Kamby C., Schou G., von der Maase H. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer. 1994 Jul 1;74(1):123–133. doi: 10.1002/1097-0142(19940701)74:1<123::aid-cncr2820740121>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  14. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Jr, Bander N., Weiselberg L. R. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988 Mar;139(3):461–469. doi: 10.1016/s0022-5347(17)42494-3. [DOI] [PubMed] [Google Scholar]
  15. Stoter G., Splinter T. A., Child J. A., Fosså S. D., Denis L., van Oosterom A. T., de Pauw M., Sylvester R. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol. 1987 Apr;137(4):663–667. doi: 10.1016/s0022-5347(17)44168-1. [DOI] [PubMed] [Google Scholar]
  16. Stöckle M., Meyenburg W., Wellek S., Voges G., Gertenbach U., Thüroff J. W., Huber C., Hohenfellner R. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992 Aug;148(2 Pt 1):302–307. doi: 10.1016/s0022-5347(17)36578-3. [DOI] [PubMed] [Google Scholar]
  17. Tannock I., Gospodarowicz M., Connolly J., Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989 Aug;142(2 Pt 1):289–292. doi: 10.1016/s0022-5347(17)38733-5. [DOI] [PubMed] [Google Scholar]
  18. Waxman J., Abel P., James N., Farah N., O'Donoghue E. P., Mee D., Colbeck R., Sikora K., Williams G. New combination chemotherapy programme for bladder cancer. Br J Urol. 1989 Jan;63(1):68–71. doi: 10.1111/j.1464-410x.1989.tb05126.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES